Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05968599

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant Clinical Trial

Official title:
A Real-World Comparison of Clinical Outcomes in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Initiated Enzalutamide vs. Abiraterone Acetate (Abiraterone) in Flatiron Electronic Health Record (EHR) Database

Clinical Trial Summary

The purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Most prostate cancers need male sex hormones, such as testosterone, to grow. Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels is known as "castration-resistant". Metastatic cancer is a cancer that has spread to other parts of the body. This is a real-world study, not a clinical trial. This means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from the Flatiron Electronic Health Record (EHR) database. The study will include patients' information from the database for men who: - Were confirmed by medical tests to have mCRPC - Started first-line treatment with enzalutamide or abiraterone (index date) for mCRPC - Had not received chemotherapy treatment before index date - Were 18 years of age or older on index date Men who are part of this study will receive enzalutamide or abiraterone as part of their usual treatment for mCRPC. We will compare the following between men receiving enzalutamide and men receiving abiraterone: - time from treatment start until death, - treatment duration, and - time to next treatment. This study will use patient information from the database until the end of information that is available.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05968599
Study type Observational
Source Pfizer
Contact
Status Active, not recruiting
Phase
Start date July 24, 2023
Completion date March 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas Phase 1/Phase 2
Withdrawn NCT03325127 - Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Withdrawn NCT02906605 - A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer Phase 2
Recruiting NCT05743621 - Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer Phase 1
Completed NCT02204072 - BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) Phase 1
Recruiting NCT05393791 - Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC Phase 2
Active, not recruiting NCT03927391 - Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects Phase 4
Completed NCT02450812 - Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany
Not yet recruiting NCT06353386 - Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Phase 1/Phase 2
Active, not recruiting NCT03431350 - A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT03822845 - Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer Phase 2/Phase 3
Completed NCT02162836 - A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 1
Completed NCT02899104 - Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
Active, not recruiting NCT04381832 - Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Phase 1/Phase 2
Completed NCT03563014 - A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
Active, not recruiting NCT02803437 - Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Recruiting NCT05944237 - HTL0039732 in Participants With Advanced Solid Tumours Phase 1/Phase 2
Withdrawn NCT03173859 - Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients Phase 2
Terminated NCT02057666 - Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer Phase 3
Active, not recruiting NCT04717154 - Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer Phase 2